tbuckley/cabot-search huggingface dataset:
Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An analysis based on the ALTER01031 trial.
Authors: Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan Cheng
Journal: Journal of Clinical Oncology (2020)

6526 Background: Calcitonin (Ct) is the most important biomarker for medullary thyroid carcinoma (MTC). In a randomized, placebo-controlled phase IIb trial (ALTER01031, NCT02586350) for MTC, anlotinib exhibited a strong capability not only in PFS prolongation but also in decreasing Ct level. This subanalysis explored the relationship between Ct level and anlotinib efficacy in this trial. Methods: Serum Ct of patients (pts) were tested at baseline and on week 6 (after 2 treatment cycles). Correlation between changes in Ct level and changes in target lesion diameters was explored. The influence of baseline Ct level on median PFS for anlotinib treated pts was estimated. Finally, pts in anlotinib arm were divided into two subgroups based on the percentage decline of Ct levels (&gt; 50% vs. ≤50%) at week 6. Median PFS (mPFS), median OS (mOS) and objective response rate (ORR) of two groups were compared. Results: 86 of 91 enrolled pts (58 in anlotinib arm and 28 in placebo arm) were recorded their serum Ct levels at baseline and no significant difference was observed between two arms (7990.0 ng/L vs. 10891.5 ng/L, P = 0.192). After 2 treatment cycles, the Ct level decreased to 4597.5 ng/L in anlotinib arm (n = 50) while increased slightly in placebo arm (12640.0 ng/L, n = 24, P = 0.006). For 49 pts in anlotinib arm who had complete assessments at baseline and week 6, roughly linear relationship was observed between Ct levels (X-axis) and target lesion diameters (Y-axis) in percent changes from baseline to week 6 (y = 0.175x – 0.049; r = 0.352, P = 0.016, excluding 3 outliers). Pts with less baseline Ct level (≤ median value vs. &gt; median value) did not show more PFS benefit (17.7 vs. 22.4 months, P = 0.802). However, after 2 treatment cycles, a trend of better survival and higher response was observed in pts with high percentage decline of Ct level (&gt; 50%, n = 25) than those with low percentage decline (≤50%, n =25) although without statistical difference (data presented in the table below). Conclusions: In ALTER01031, anlotinib showed a strong capability in rapidly decreasing serum Ct. Lower baseline Ct level does not mean better prognosis while a rapid Ct decrease may predict improved survival and treatment response to MTC pts received anlotinib. Clinical trial information: NCT02586350 . [Table: see text]
A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304).
Authors: Matthew Ingham, Michelle R. Mahoney, Fabrizio Remotti, Ardaman Shergill, Mark Andrew Dickson, Richard F. Riedel, Steven Attia, Anthony D. Elias, David A. Liebner, Mark Agulnik, Katherine Anne Thornton, Varun Monga, Brian Andrew Van Tine, Gary K. Schwartz, William D. Tap
Journal: Journal of Clinical Oncology (2020)

11562 Background: Soft tissue sarcoma (STS) is a heterogeneous malignancy of connective tissue. Although mTOR is implicated in STS pathogenesis, clinical activity from mTORC1 inhibitors is modest. M, a potent selective mTORC1/mTORC2 inhibitor, was more effective in STS preclinical models than inhibitors of mTORC1, IGF1R and mTORC1+IGF1R, owing to more complete suppression of PI3K/AKT/mTOR and abrogation of feedback AKT activation. P, an oral multikinase inhibitor, is approved for non-adipocytic STS and often used after progression (PD) on chemotherapy. In phase 1, the RP2D of M was 30 mg weekly. A091304 was to evaluate M as a novel targeted therapy for STS. Methods: In A091304, pts were randomized 1:1 to M 30 mg weekly or P 800 mg daily. Eligibility required Eastern Cooperative Oncology Group PS ≤ 1, progression on ≥ 1 prior chemotherapy and specific STS subtypes (cohort 1: UPS; 2: LMS; 3: MPNST, SS). Crossover to M was allowed after PD on P. 1° endpoint was progression-free survival (PFS). Assuming median PFS of P was 4.6 months (mo), 98 pts yielded 80% power to detect a hazard ratio of 0.66 favoring M [1-sided test, alpha = 0.15] and including 1 planned futility analysis. 2° endpoints were response rate, clinical benefit rate (CBR) at 4 mo and safety. After 4 of the first 12 pts randomized to P experienced ≥ grade (gr) 3 toxicity, the study was amended to begin at P 400 mg, allowing titration to 800 per investigator discretion. Results: After protocol amendment, 114 pt underwent randomization (M: 56, P: 58), and 111 initiated treatment. Median PFS was 2 mo for M and 2.1 mo for P (HR = 1.47; 1-sided 85% upper confidence boundary = 1.85), with 2 partial responses in each arm. CBR was 5.4% for M and 13.8% for P. Median OS was 10.7 mo for M and 13.9 mo for P (HR = 1.41; 95% CI 0.80-2.49). 26/43 pt with PD on P crossed over to M. Median PFS after crossover was 1.8 mo (95% CI 1.5-3.5). Gr 3 drug-related adverse events (AEs) occurred in 36% on M and 41% on P; gr 4 toxicity was rare. AEs were consistent with known effects of M and P. Conclusions: P at 400 mg daily (allowing escalation to 800 mg per investigator discretion) demonstrated a shorter PFS as compared prior randomized studies with P. Despite this, M failed to demonstrate superior clinical activity as compared to P at the interim analysis. Further work will examine activity within histology-specific cohorts and evaluate available tissue samples for evidence of pharmacodynamic activity. Support: U10CA180821, U10CA180882, U10CA180888, UG1CA233324 (SWOG); https://acknowledgments.alliancefound.org . Clinical trial information: NCT02601209 .
Association of losartan use with outcomes in metastatic pancreatic cancer patients treated with chemotherapy.
Authors: Jessica Allen, Kathan Mehta, Shrikant Anant, Prasad Dandawate, Anwaar Saeed, Anup Kasi
Journal: Journal of Clinical Oncology (2020)

e16738 Background: A phase II trial has shown improved efficacy of neoadjuvant therapy when combined with losartan (by remodeling desmoplasia) in locally advanced pancreatic ductal adenocarcinoma (PDA). However, role of losartan is unknown in metastatic PDA. We examined the relationship between the use of the angiotensin II receptor antagonist, losartan, at time of diagnosis with clinical outcomes in metastatic PDA pts that received chemo. Methods: We retrospectively evaluated 114 metastatic PDA pts treated at our center between Jan 2000 and Nov 2019. We compared OS, PFS, objective response rate (ORR), and disease control rate (DCR) between pts using losartan at time of cancer diagnosis and a control group of pts not on losartan. A subanalysis was performed based on losartan dose: 100mg dose versus control pts. and based on chemo: FOLFIRINOX or gemcitabine+abraxane. Results: Table shows baseline demographics. No significant difference was found in OS [p = 0.455] or PFS [p = 0.919] in pts on losartan (median 274d, 83d) vs control (median 279d, 111d) [p = 0.466]. No significant difference was found in ORR [p = 0.621] or in DCR [p = 0.497]. No significant difference was found in OS [p = 0.771] or PFS [p = 0.064] in losartan pts (median 347d, 350d) vs control (median 333d, 101d) treated with FOLFIRINOX. No significant difference was found in OS [p = 0.916] or PFS [p = 0.341] in losartan (median 312d, 69d) vs control (median 221d, 136d) [p = 0.916] treated with gemcitabine+abraxane. No significant difference was found in OS [p = 0.727] or PFS [p = 0.790] in 100mg losartan pts (median 261d, 84d) vs control (median 279d, 111d). Conclusions: Pts on losartan at time of diagnosis had no significant difference in OS, PFS, ORR, DCR than control pts. However, a subanalysis of pts treated with FOLFIRINOX revealed a longer PFS with losartan than control but did not meet statistical significance, likely due to small sample size. To confirm if the benefit of losartan + FOLFIRINOX seen in neoadjuvant setting for locally advanced cancer also applies to metastatic cancer, our findings need to be validated in a larger cohort. [Table: see text]
Pay more attention to diagnosis and management of patients with impaired fasting glucose and glucose tolerance
Authors: 卜石, 杨文英
Journal: BMJ (2009)

糖尿病前期的概念包括空腹血糖受损(impaired fasting glucose,IFG)和糖耐量减低(impaired glucose tolerance,IGT)或两者兼有,判断标准IFG为空腹血糖6.1～6.9 mmol/L,IGT为口服葡萄糖耐量试验(OGTT)后2 h血糖7.8～11.0 mmol/L.美国糖尿病学会(ADA)提出的IFG切点为＞5.6 mmol/L,但因目前对空腹血糖为5.6～6.0 mmol/L人群发生大血管病变的危险性是否明显增加尚缺乏充分的证据,我国空腹血糖异常的切点仍用WHO的标准。
Application of circulating tumor DNA in diagnosis and prognosis of epithelial ovarian cancer
Authors: Dongying Wang, Fei Wu, Weiyang Zhang
Journal: BMJ (2018)

In the development of cancer, the DNA fragments of tumor cells enter into the blood circulation to form circulating tumor DNA (ctDNA), which is an indicator for detecting and quantifying tumor mutations. Epithelial ovarian cancer accounts for most of the histological types in ovarian cancer. This article reviews the clinical application of ctDNA in epithelial ovarian cancer, including the early diagnosis, therapeutic effect evaluation after operation and adjuvant therapy, tumor load assessment, dynamic monitoring during the follow-up and the prognosis of patients.


Key words: 
DNA, Neoplasm; Ovarian neoplasms, epithelium; Neoplastic cells, circulating; Cell-free DNA; Tumor biomarkers,biological
Early diagnostic and prognostic value of procalcitonin in critical ill patients with sepsis
Authors: 王明刚, 李春盛, 杨军, 王硕
Journal: BMJ (2007)

目的 探讨降钙素原(procalcitonin,PCT)对危重症患者合并脓毒症的早期诊断意义.方法 30例符合全身炎症反应综合征诊断的急诊ICU住院患者.根据入院时的临床表现及相关检验分为脓毒症组18例和非脓毒症组12例,所有患者入院第1、3、7天分别抽血检测降钙素原、C反应蛋白和外周血白细胞计数,同时行血、痰细菌培养、胸片检查,采用急性生理和慢性健康状况评分(APACHEⅡ)评估患者病情程度.随访28 d判断预后.结果 降钙素原在脓毒症组升高明显(最高10.13 ng/ml),非脓毒症组变化不明显,降钙素原高于0.5 ng/ml诊断脓毒症的敏感性为97.0%,特异性为91.7%,其阳性预测值达到82.1%,均高于C反应蛋白和白细胞计数.降钙素原的浓度与预后有关,死亡组明显高于存活组.降钙素原和白细胞计数在两组均升高,但各组间差异无统计学意义.结论 降钙素原可以作为判断脓毒症的早期指标,而且可能反映病情程度,预测预后。
Selection of a set of quality indicators (QIs) for oncological clinical pathway with patient associations and healthcare professionals.
Authors: Mario Di Palma, Aude Fourcade, Marie Ferrua, Mariem Chirrane, Mikaël Daouphars, Virginie Berger, Béatrice Clairaz-Mahiou, Yvonnick Bezie, Audrey Garibbo, Sylvie Giacchetti, Christophe Tournigand, Etienne Minvielle
Journal: Journal of Clinical Oncology (2020)

e19221 Background: Clinical pathways in oncology are increasingly complex and involve many healthcare professionals inside and outside the hospital. The available QIs focus on hospital care, few of them describe the entire clinical pathway. Our objective is to select a set of QIs for oncological clinical pathway by involving hospital professionnals, patient associations and non-hospital professionals (GPs, pharmacists and private nurses). The step described concerns the research conducted with hospital professionals and 11 patient associations. Methods: A review of available QIs assessing the clinical pathway was conducted from the gray literature and literature reviews. Selection criteria were applied to extract oncological clinical pathway indicators. The list of identified QIs was submitted to two working groups: hospital professionals (26 oncologists, pharmacists and SRNs of various hospitals in France) and patient associations. Two meetings in each group were necessary. The first one to select by consensus (nominal group) the QIs on the basis of their rating on relevance and feasibility. The second, to describe precisely the QIs selected. Results: 5731 QIs were identified in the initiatives, 131 QIs related to oncological clinical pathway were presented. 10 QIs were selected by hospital professionals: outcome (2), process (3) and structure (5). 10 QIs were retained by patient associations: process (4), structure (2) and outcome (4). Both groups selected QIs on symptom assessment, adherence to treatment, access to palliative care and management of patients receiving oral therapy. They also emphasized the need to gather information directly from patients by selecting PREMS on patients’ experience and PROMS on quality of life, emotional state, symptoms and toxicity. Conclusions: The QIs selected responds to a real need for oncological clinical pathway in France. The next step will be to carry out the same work with non hospital professionals to have a representative set of all actors. The QIs will then be collected from the hospitals experts in France and in Europe to validate their metrological qualities.
Implementation of community rotation in residency training of general practice
Authors: Qian Chen, Tianhao Wang
Journal: BMJ (2017)

The community rotation is an important stage of standardized residency training for general practitioners (GPs). However, the community rotation is also considered as a most difficult part of the GP residency training because of the problems in training management and evaluation. Based on our experiences of 7-months community training, we expanded the duration of community training to 1 year, and implemented a new segmentation and multipoint practice plan in Zhongshan hospital. This is a new attempt for GP residency training, which would hopefully meet the international standards of GP residency training.


Key words: 
Community health centers; Training; General practitioners
The clinical study on early minimal feeding of very low birth weight infant
Authors: 陈震, 陈静, 杨震英, 邵宪花
Journal: BMJ (2006)

目的 探讨早期经口微量喂养对极低出生体重儿营养状况、喂养并发症及远期预后的影响.方法 将2002年1月至2004年12月收治的90例极低出生体重儿按随机编号分为:早期经口微量喂养组30例(采用早期经口微量喂养),胃管组30例(采用常规胃管喂养),全静脉营养组30例(采用全静脉营养).比较3组的喂养不耐受发生情况、恢复出生体重时间、平均日增长克数、达到全肠道营养时间、住院天数及并发症等.结果 早期经口微量喂养组、胃管组、全静脉营养组恢复出生体重的时间分别为(14.1± 4.0)d、(13.8±3.5)d、(13.5±3.8)d,差异无统计学意义(P＞0.05).早期经口微量喂养组平均每日体重增长克数、达到全肠道营养时间、住院天数、喂养不耐受发生率分别为(20.8±7.0)g/d、(24.3±2.1)d、(28.7±3.5)d、27%,与胃管组及全静脉营养组相比,差异有统计学意义(P＜0.01);其血糖紊乱发生率(33%)与胃管组(32%)相比差异无统计学意义(P＞0.05),与全静脉营养组(68%)相比差异有统计学意义(P＜0.05);发生喂养并发症如呼吸暂停、呕吐、腹胀、胃出血与胃管组相比差异有统计学意义(P＜0.01);发生窒息、吸入性肺炎、腹泻、坏死性小肠结肠炎、胃穿孔与胃管组相比,差异无统计学意义(P＞0.05).随访结果表明,1.5岁时胃管组和全静脉营养组各有1例发生脑瘫,全静脉营养组有1例发生精神发育迟滞.结论 对极低出生体重儿宜提倡早吸吮、早期微量喂养,以减少喂养相关并发症的发生,缩短住院天数,减少后遗症的发生。
Analysis of etiology and drug use in the chronic systolic heart failure patients in two community health service centers of Pudong district in Shanghai
Authors: Ni Lan, Zhang Yumin, Xue Jinhua
Journal: BMJ (2016)

Objective
To investigate the treatment of chronic heart failure in two communities in Pudong and find the deficiency of standardized treatment in community hospital.


Methods
A retrospective study of all the inpatient, family bed and outpatient with heart failure who visit Hudong and Lujiazui community health Service center was conducted from March 2012 to March 2015 retrospectively. General situation(gender, age, smoking history, drinking history, daily salt intake, concomitant disease), etiology and if have the acute heart failure onset in half a year and what are the incentives, drug treatment and treatment of concomitant hypertension and diabetes mellitus were analyzed by face to face follow up.


Results
The study included 300 patients, average age was (58±10) years. Daily salt intake of 55.0%(165/300) patients was more than 9 g. Coronary heart disease(45.7%, 137/300), hypertension (30.7%, 92/300)and cardiomyopathy (9.0%, 27/300)were the chief heart failure etiology. 59.3%(178/300)patients had acute heart failure in half a year.Acute blood pressure(20.8%, 37/178), transfusion too fast or too much and infection(14.6%, 26/178)were the chief incentives leading to acute heart failure. 83.3%(250/300)patients used ACEI/ARB, but only 32.0%(80/250)of them applied the target dose. 53.7%(161/300)patients used beta blockers and 98.1%(158/161)of them could not reach the target dose. Tartaric acid metoprolol(51.6%, 83/161), peso parlour(18.6%, 30/161)and carvedilol(14.9%, 24/161)were commonly used drug in clinic. 76.6%(230/300)patients had hypertension and blood pressure was controlled in 82.2%(189/230)of them successfully. 44.0%(132/300)patients had diabetes mellitus and glycosylated hemoglobin(HbA1c)was controlled from 7% to 8% in 23.5%(31/132)of them.


Conclusion
In the community treatment of heart failure, the drugs recommended by guidelines were low usage and achieved the target dose rarely. Treatment of concomitant diseases was not good. The knowledge of new progress was not enough.


Key words: 
Heart failure, systolic; Community health centers; General practitioner; Standardized treatment
Trainee and workforce diversity in hematology and oncology: Ten years later what has changed?
Authors: Ana I. Velazquez Manana, Ryan Leibrandt, Narjust Duma
Journal: Journal of Clinical Oncology (2020)

11000 Background: The diversification of the healthcare workforce has been identified as a strategy to address health disparities and increase patient-physician trust. A prior review of diversity among oncology fellows up to 2010, showed an increase in female representation over 17 years, but no change in underrepresented minorities (URM). We aim to assess the changes in hematology and oncology (HO) fellowship diversity over the last decade and how this compares to our workforce. Methods: Publicly available registries were used to assess differences among female and URM HO fellows, HO fellowship applicants, internal medicine (IM) academic faculty, IM residents, medical school graduates (MSG), and the US population in 2019. These were compared to the 2016 HO practicing physicians. Changes in URM and female HO fellow representation from 2009 to 2019 were assessed. Data was analyzed using binomial tests and simple linear regression models. Results: Female representation among HO fellows (43.8%) was increased when compared with HO practicing physicians (+11.8%, p &lt; 0.0001) and IM faculty (+3.2%, p = 0.0079); no difference from IM residents or HO applicants. Female HO fellows were underrepresented when compared with MSG (-4.0%, p = 0.0014) and US population (P &lt; 0.0001). Hispanic HO fellows (6.1%) had increased representation when compared to IM faculty (+2.7%, p &lt; 0.0001), but were underrepresented when compared to IM residents (-2.2%, p = 0.0012) and US population (p &lt; 0.0001). The proportion of Hispanic HO fellows was no different when compared to HO practicing physicians, HO applicants, and MSG. African American (AA) fellows (3.8%) were underrepresented when compared to IM residents (-2.0%, p = 0.0005), HO applicants (-1.7%, p = 0.0465), MSG (-2.4%, p = 0.0001), and US population (p &lt; 0.0001). AA fellows were increased when compared to HO practicing physicians (+1.5%, p = 0.0002), but no different than IM faculty. Asian HO fellows were increased when compared to IM residents, MSG, and US population. Over the last 10 years there has been no significant change in the proportion of AA or female HO fellow representation, with a decreasing trend in Hispanics (-0.14% per year, p = 0.04).Conclusions: The current state of diversity in HO workforce still requires attention. Despite ongoing efforts, females, AA, and Hispanics continue to be underrepresented. The decreasing trend in Hispanic representation and clear differences in diversity between HO fellowships and IM residencies calls for action among fellowship programs and national societies to increase URM engagement and recruitment.
左前降支远端病变致局限下壁心肌梗死二例
Authors: 谭安安, 夏豪, 周桃, 胡波
Journal: BMJ (2007)

急性下壁心肌梗死患者的梗死相关动脉具有多变性,以左前降支远端为梗死相关动脉的下壁心肌梗死少见报道.2006年9月我院收治2例男性下壁心肌梗死患者,冠状动脉造影显示为左前降支远端狭窄,报告如下。
中华医学会全科医学分会第八次学术年会纪要
Authors: 顾湲
Journal: BMJ (2010)

中华医学会全科医学分会第八次学术年会于2010年8月20日至23日在上海光大会展中心召开.参会代表900多人,分别来自27个省、市、自治区,是中华医学会全科医学分会成立以来规模最大的一次年会.大会共收到论文356篇,文章的质量、涉及的深度和广度较以往均有了明显提高。
Whole-Genome Sequencing Identifies Novel Functional Loci Associated with Lung Function in Puerto Rican Youth
Authors: Eunice Y. Lee, Angel C. Y. Mak, Donglei Hu, Satria Sajuthi, Marquitta J. White, Kevin L. Keys, Walter Eckalbar, Luke Bonser, Scott Huntsman, Cydney Urbanek, Celeste Eng, Deepti Jain, Gonçalo Abecasis, Hyun M. Kang, Soren Germer, Michael C. Zody, Deborah A. Nickerson, David Erle, Elad Ziv, Jose Rodriguez-Santana, Max A. Seibold, Esteban G. Burchard
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Puerto Ricans have the highest childhood asthma prevalence in the United States (23.6%); however, the etiology is uncertain.
The anti-disialoganglioside (GD2) antibody dinutuximab (D) for second-line treatment (2LT) of patients (pts) with relapsed/refractory small cell lung cancer (RR SCLC): Results from part II of the open-label, randomized, phase II/III distinct study.
Authors: Martin Edelman, Mikhail Dvorkin, Konstantin K. Laktionov, Alejandro Navarro, Oscar Juan-Vidal, Vadim Kozlov, Gil Golden, Odette Jordan, CQ Deng
Journal: Journal of Clinical Oncology (2020)

9017 Background: Although SCLC is highly responsive to initial therapy, most pts relapse &lt; 1 y. Topotecan (T) and irinotecan (I) are used in 2LT of SCLC; however, treatment response is low: ≤10-25% and median survival is ~4-5 months. Preclinical studies support GD2 as an SCLC target. This study evaluated the combination of D+I vs. I alone or T alone in 2LT of SCLC pts. Methods: Pts with RR SCLC, Eastern Cooperative Oncology Group 0-1, were randomized 2:2:1 to receive D 16-17.5 mg/m 2 intravenously (IV) plus I 350 mg/m 2 IV (Day 1 q21d), I 350 mg/m 2 IV (Day 1 q21d), or T 1.5 mg/m 2 IV (Days 1-5 q21d). Randomization was stratified by duration of response to prior platinum therapy. Primary endpoint was overall survival (OS) in pts treated with D+I vs. I alone and was analyzed using stratified log-rank test and COX regression. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and clinical benefit rate, ORR + stable disease (CBR). Safety was assessed. Results: 471 pts were randomized to D+I (n = 187), I (n = 190), or T (n = 94). Baseline characteristics were balanced (24.2% women; mean ± SD age 61.6 ± 8.7 y). Median OS was similar in pts receiving D+I (6.9 [3.5,10.9] months) vs. I alone (7 [3.6,13.1] months) (HR [95% CI]: 1.12 [0.9,1.4]; P = 0.3132) or T alone (7.4 [3.8,12.8] months) (HR [95% CI]: 1.05 [0.8,1.37]; P = 0.7233). Median PFS was similar in pts receiving D+I (3.5 [1.5,6.2] months) vs. I (3 [1.4,5.7] months) or T (3.4 [1.6, 6.1] months) alone. ORR was similar in pts receiving D+I (17.1%) vs. I (18.9%) or T (20.1%) alone. CBR was similar in pts receiving D+I (67.4%) vs. I (58.9%) or T (68.1%) alone. Grade 3 or higher adverse events were experienced by 77% D+I, 69.5% I, and 86.4% T pts. Conclusions: Treatment with D+I was not superior to established 2LT for RR SCLC. Exploratory analyses are ongoing to evaluate GD2 expression in circulating tumor cells, select protein biomarkers, and any correlative impact on observed response. Clinical trial information: NCT03098030.
玻璃体切割联合眼内光凝治疗糖尿病玻璃体积血疗效观察
Authors: 孙鼎, 李广涛, 叶俊杰
Journal: BMJ (2006)

回顾性分析临沂市人民医院1998年至2004年行玻璃体切割术治疗糖尿病性视网膜病变玻璃体积血的25例26眼,均处于增生早期的增殖期视网膜病变,术中尽量保留晶体,联合眼内全视网膜光凝.结果提示,在玻璃体积血1～3个月时及时行玻璃体切除术,并同时在术中行足量有效的眼内光凝,可以提高手术疗效,降低糖尿病性视网膜病变的致盲率。
血清C反应蛋白检测与冠心病的关系
Authors: 孔令文, 吴莉, 赵海山, 郭蕾, 刘晓静, 石健, 闫丽妲, 邓芳
Journal: BMJ (2004)

有研究发现炎性细胞因子升高和血管内皮细胞损伤可使内皮功能下降,从而促进动脉硬化斑块形成[1].C反应蛋白(CRP)作为一种炎症标志物,其合成受白细胞介素6(IL-6)、肿瘤坏死因子α(TNFα)的调控,血清CRP水平能很好地反应机体细胞因子的变化.我们对血清CRP与冠心病患者病变程度和病变积分的相关性做了进一步探讨。
阅读X线胸片
Authors: 吴东, 陈嘉林
Journal: BMJ (2010)

一、首先要评估胸片的质量 X线胸片是临床广泛应用的影像检查.不仅放射科和呼吸科医生需要经常阅读胸片,作为临床基本功之一,掌握正确的读片方法对各专科和全科医生也很有意义.有经验的医生拿到一张胸片后,并不急于马上观察有无病变,而是先评价胸片质量,包括照射条件、患者体位、有无伪影等,这些因素都可能对成像造成影响。